- Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.
- Fasano GA, Bayard S, Chen Y, Marti J, Simmons R, Swistel A, Bensenhaver J, Davis M, Newman L.
- Ann Surg Oncol. 2023 Jan 21. doi: 10.1245/s10434-022-13056-0. Epub ahead of print.
- PMID: 36681737
- PubMed abstract
- Source abstract
- Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition.
- Kumpula TA, Koivuluoma S, Soikkonen L, Vorimo S, Moilanen J, Winqvist R, Mantere T, Kuismin O, Pylkäs K.
- Fam Cancer. 2023 Jan 19. doi: 10.1007/s10689-023-00327-2. Epub ahead of print.
- PMID: 36653541
- PubMed abstract
- Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
- Berger BT, Labriola MK, Antonarakis ES, Armstrong AJ.
- BMJ Case Rep. 2023 Jan 18;16(1):e251320. doi: 10.1136/bcr-2022-251320.
- PMID: 36653039
- PubMed abstract
- Source abstract
- Case report
- Inference on the Genetic Architecture of Breast Cancer Risk.
- Yasui Y, Letsou W, Wang F, Im C, Sapkota Y, Wang Z, Mirzaei Salehabadi S, Baedke JL, Moon WJ, Liu Q, Robison LL, Martinez JM.
- Cancer Epidemiol Biomarkers Prev. 2023 Jan 18:EPI-22-1073. doi: 10.1158/1055-9965.EPI-22-1073. Epub ahead of print.
- PMID: 36652676
- PubMed abstract
- Source abstract
- Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
- Gerald T, Margulis V, Meng X, Bagrodia A, Cole S, Qin Q, Call SG, Mauer E, Lotan Y, Woldu SL.
- Urol Oncol. 2023 Jan 16:S1078-1439(22)00493-8. doi: 10.1016/j.urolonc.2022.12.008. Epub ahead of print.
- PMID: 36653279
- PubMed abstract
- Source abstract
- Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
- Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, Lin Y, Liu Z, Cao Y, Zhang G, Shang S, Zhang Y, Wang K.
- JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337.
- PMID: 36652665
- PubMed abstract
- Source abstract
•• Identifier: NCT03154749: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 18.)